Jodi Klein Glaisher, OTR | |
461 Brooky Lane, Fraser, CO 80442-0593 | |
(970) 531-9460 | |
(970) 726-5337 |
Full Name | Jodi Klein Glaisher |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 461 Brooky Lane, Fraser, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902077167 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jodi Klein Glaisher, OTR Po Box 593, Fraser, CO 80442-0593 Ph: (970) 531-9460 | Jodi Klein Glaisher, OTR 461 Brooky Lane, Fraser, CO 80442-0593 Ph: (970) 531-9460 |
News Archive
Nearly nine out of 10 nursing home physicians said that using their mobile devices to look up prescription drug information prevented at least one adverse drug event in the previous month, according to a University of Pittsburgh School of Medicine Department of Biomedical Informatics study published last week in the Journal of the American Medical Directors Association.
Preclinical research from VCU Massey Cancer Center published recently in the Proceedings of the National Academy of Sciences shows that the combination of two existing drugs can exploit the metabolic "hunger" of a particularly aggressive type of neuroblastoma to kill cancer cells without inflicting too much collateral damage to healthy tissue.
In a new study published today in the journal Developmental Science, researchers from the Kennedy Krieger Institute and Vanderbilt University found that early motor experiences can shape infants' preferences for objects and faces.
A new University of British Columbia study identifies an important molecular change that occurs in the brain when we learn and remember.
Genentech, a member of the Roche Group, today announced it will make its first milestone payment to ForSight VISION4, Inc. as part of an exclusive license agreement to develop the company's investigational drug delivery device, designed to provide sustained delivery of Lucentis (ranibizumab).
› Verified 3 days ago